

***Information for Pharmacists***

**Claims Submission Procedure –  
Anagrelide 0.5 mg Capsules**

***Effective June 5 ,2025***

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

**\*\*Pharmacies do NOT receive drug interaction information when submitting claims using PINs. Please review all claims carefully prior to submitting\*\***

- There is variable supply of commercially available Anagrelide 0.5 mg capsules (DIN: 02274949).
- Anagrelide 0.5mg capsules are a benefit under the Home Cancer Drug Program.
- Due to this shortage, Manitoba is outlining the following product selection tree. This selection tree is to encourage pharmacy providers to use existing commercial supply while outlining an alternative option if supply is unavailable:
  - Commercially available product should be dispensed if the pharmacy has inventory on hand or can obtain product through normal distribution channels;
  - The pharmacy vendor may obtain commercially available product from another provider (e.g., another member within the same chain);
  - If commercially available product cannot be obtained, then Australian-labeled Anagrelide 0.5 mg capsules should be dispensed.
- The following PIN should be used when submitting claims for Australian-labeled Anagrelide 0.5 mg capsules:  
  
PIN: 00912096
- Manitoba will inform pharmacy providers once the shortage has been resolved and the PIN is no longer required and has been withdrawn for coverage.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:

<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to [NIBDrugShortages@gov.mb.ca](mailto:NIBDrugShortages@gov.mb.ca)